RT Journal Article
SR Electronic
T1 A sagittal gradient of pathological and compensatory effects of neurophysiological slowing in Parkinson’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.05.22278436
DO 10.1101/2022.08.05.22278436
A1 Wiesman, Alex I.
A1 da Silva Castanheira, Jason
A1 Degroot, Clotilde
A1 Fon, Edward A.
A1 Baillet, Sylvain
A1 ,
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/08/08/2022.08.05.22278436.abstract
AB Using magnetoencephalographic imaging and extensive clinical and neuropsychological assessments, we show that patients with Parkinson’s disease (PD; N = 79) exhibit a slowing of neurophysiological activity relative to healthy adults (N = 65), which relates to motor and cognitive abilities. Importantly, the association between neurophysiological slowing and PD clinical features varies systematically across the cortex along a sagittal gradient: cortical slowing is associated with worse impairment in dorsal-posterior cortices, and this association is reversed in ventral-anterior cortical regions. This pathological-to- compensatory anatomical gradient is sensitive to differences in patients’ individual clinical profiles, and co- localizes with normative atlases of neurotransmitter receptor/transporter density. Long-range functional connectivity between posterior regions and parietal and frontal cortices is also significantly shifted towards lower frequencies in PD, demonstrating a novel network-level slowing effect. Taken together, these findings demonstrate the multifaceted nature of neurophysiological slowing in patients with PD, with anatomically-dependent clinical relevance to motor and cognitive symptoms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grant F32-NS119375 to AIW from the United States National Institutes of Health (NIH); to JDSC as a doctoral fellowship from Natural Science and Engineering Research Council of Canada (NSERC); to EAF as a Foundation Grant from the Canadian Institutes of Health Research (CIHR; FDN-154301) and the CIHR Canada Research Chair (Tier 1) of Parkinson's Disease; and to SB from by a NSERC Discovery grant, the Healthy Brains for Healthy Lives initiative of McGill University under the Canada First Research Excellence Fund, the CIHR Canada Research Chair (Tier 1) of Neural Dynamics of Brain Systems and the NIH (1R01EB026299). Data collection and sharing for this project was provided by the Quebec Parkinson Network (QPN), the Pre-symptomatic Evaluation of Novel or Experimental Treatments for Alzheimer's Disease (PREVENT-AD; release 6.0) program, and the Open MEG Archives (OMEGA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The QPN is funded by a grant from Fonds de recherche du Québec - Santé (FRQS). PREVENT-AD was launched in 2011 as a $13.5 million, 7-year public-private partnership using funds provided by McGill University, the FRQS, an unrestricted research grant from Pfizer Canada, the Levesque Foundation, the Douglas Hospital Research Centre and Foundation, the Government of Canada, and the Canada Fund for Innovation. Private sector contributions are facilitated by the Development Office of the McGill University Faculty of Medicine and by the Douglas Hospital Research Centre Foundation (http://www.douglas.qc.ca/). OMEGA and the Brainstorm app are supported by funding to SB from the NIH (R01-EB026299), a Discovery grant from the Natural Science and Engineering Research Council of Canada (436355-13), the CIHR Canada research Chair in Neural Dynamics of Brain Systems, the Brain Canada Foundation with support from Health Canada, and the Innovative Ideas program from the Canada First Research Excellence Fund, awarded to McGill University for the HBHL initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Research Ethics Board at the Montreal Neurological Institute reviewed and approved this study. Written informed consent was obtained from every participant following detailed description of the study, and all research protocols complied with the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in the preparation of this work are available through the Clinical Biospecimen Imaging and Genetic (C-BIG) repository (https://www.mcgill.ca/neuro/open-science/c-big-repository), the PREVENT-AD open resource (https://openpreventad.loris.ca/), and the OMEGA repository (https://www.mcgill.ca/bic/resources/omega). Normative neurotransmitter density data are available from neuromaps (https://github.com/netneurolab/neuromaps). Code for MEG preprocessing and the neurophysiological slowing and spatial gradient analyses is available at https://github.com/aiwiesman/QPN_Slowing. Rejection of epochs containing artifacts was performed with the ArtifactScanTool (https://github.com/nichrishayes/ArtifactScanTool). https://www.mcgill.ca/neuro/open-science/c-big-repository https://openpreventad.loris.ca/ https://www.mcgill.ca/bic/resources/omega https://github.com/netneurolab/neuromaps https://github.com/aiwiesman/QPN_Slowing